Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Inclusion Criteria:

* Patients with a histologic or cytologic diagnosis of carcinoma of the gastroesophageal junction or esophagus;
* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria;
* Overexpression of EGFR defined by immunohistochemistry (3+) or gene amplification by fluorescence in-situ hybridisation;
* Have progressed after one chemotherapy regimen;
* Age 18-75 years old with performance status of 0 to 2

Exclusion Criteria:

* Prior targeted therapy with erlotinib, gefitinib, and so on
* Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).
* Known severe hypersensitivity to icotinib or any of the excipients of this product.
* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.